Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations.
Giuntoli
S
S
Rovida
E
E
Barbetti
V
V
Cipolleschi
M G
MG
Olivotto
M
M
Dello Sbarba
P
P
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D015687:Cell Hypoxia / Q000502:physiology; D002999:Clone Cells; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D010100:Oxygen / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D010100:Oxygen